Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMX-101 in CIS Bladder Cancer
NCT01731652Phase 2Completed
- Sponsor
- Telormedix
- Start
- Feb 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TMX-101 in bladder carcinoma in situ (CIS), sponsored by Telormedix. Primary endpoint: Complete Response. Started Feb 2013; status: completed.
02
Drugs
TMX-101
03
Conditions
bladder carcinoma in situ (CIS)
Beyond the preview
Go deeper on NCT01731652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731652.